SLC5A2 and chronic kidney disease: Furthermore, alongside a class 1A recommendation to use SGLT2 inhibitors to treat CKD in patients with eGFR ≥ 20 mL/min/1.73 m2 and a UACR ≥ 200 mg/g, the newly updated KDIGO guidelines also suggest using SGLT2 inhibitors in patients with eGFR ≥ 20 to 45 mL/min/1.73 m2 and a UACR < 200 mg/g as a class 2B recommendation.18